DeepSyte™
Bill FeedAll repsScoreboardsPrimariesProAboutSign inGet started
DeepSyte™™

A nonpartisan civic accountability tool. We match federal legislation to your stated values — without partisan bias.

Learn

  • About
  • About the name
  • Methodology
  • Glossary

Legal

  • Privacy
  • Terms of Service
  • Refund Policy
  • Contact

Sources

Bill data from Congress.gov. Summaries from the Congressional Research Service where available.

Follow

  • Bluesky — @deepsyte.app
  • X — @deepsyteapp
All content is for informational purposes only. Always verify against primary sources.
Back to bill feed
118-s-1131Committee
Sign in to get alerts

Drug Price Transparency Act of 2023

Read the record. Not the rhetoric.

See how your representatives voted on this bill.

DeepSyte matches this bill to the issues you care about and shows whether your reps' votes line up — not party, not press releases. Take the 2-minute values quiz to see your alignment.

Get started freeTake the values quiz

Alignment with your views

Sign in and take the values quiz to see how this bill lines up with what you've said.

Summary

Official CRS summary

This bill provides statutory authority for the limitation on which type of prescription drug rebates are exempt from federal anti-kickback laws. Specifically, a rebate from a drug manufacturer to a health insurer or pharmacy benefit manager is exempt only if the rebate (1) is disclosed to the consumer at the point of sale, or (2) is a flat fee paid for pharmacy benefit management services.

Read full bill text

Values analysis

Sign in and take the values quiz to get a personalized read on how this bill lines up with your positions.

Bill details

Congress
118
Bill type
s
Introduced
March 30, 2023
Sponsor
Not yet available
Last action
March 30, 2023— Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

How your representatives voted

Sign in to see how your representatives voted on this bill.